• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血栓调节蛋白(p.Cys537Stop)通过一种不寻常的膜插入/渗漏机制从细胞中释放出来。

Thrombomodulin (p.Cys537Stop) is released from cells by an unusual membrane insertion/leakage mechanism.

机构信息

Aix Marseille University, INSERM, INRAE, C2VN, Marseille, France.

Department of Hematology, Centre Hospitalier Universitaire Timone, Marseille, France.

出版信息

Blood Adv. 2024 Nov 12;8(21):5467-5478. doi: 10.1182/bloodadvances.2024013546.

DOI:10.1182/bloodadvances.2024013546
PMID:39208365
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11532747/
Abstract

Expression of the thrombomodulin (TM) variant c.1611C>A (p.Cys537Stop) leads to the synthesis of a protein with no cytoplasmic tail and a transmembrane domain shortened by 3 amino acids (TM536). However, little is known regarding the release mechanism and properties of TM536. Using umbilical vein endothelial cells and peripheral blood-derived endothelial colony-forming cells from a heterozygous carrier of the TM536 variant as well as overexpression cell models, we demonstrated that TM536 is released from cells by an unusual mechanism. First, TM536 is inserted into the endoplasmic reticulum (ER) membrane, then, because of the low hydrophobicity of its intramembrane domain, it escapes from it and follows the conventional secretory pathway to be released into the extracellular compartment without the involvement of proteolysis. This particular secretion mechanism yields a soluble TM536, which is poorly modified by chondroitin sulfate glycosaminoglycan compared with conventionally secreted soluble forms of TM, and therefore has a suboptimal capacity to mediate thrombin-dependent activation of protein C (PC). We also showed that TM536 cellular trafficking was altered, with retention in the early secretory pathway and increased sensitivity to ER-associated degradation. As expected, activation of ER-associated degradation increased TM536 degradation and reduced its release. The expression of TM536 at the cell surface was low, and its distribution in lipid raft-like membrane microdomains was altered, resulting in low thrombin-dependent PC activation on the cell surface.

摘要

血栓调节蛋白(TM)变体 c.1611C>A(p.Cys537Stop)的表达导致合成一种没有细胞质尾巴和跨膜结构域缩短 3 个氨基酸的蛋白(TM536)。然而,关于 TM536 的释放机制和性质知之甚少。我们使用携带 TM536 变体的杂合子脐静脉内皮细胞和外周血衍生的内皮细胞集落形成细胞以及过表达细胞模型,证明 TM536 通过一种不寻常的机制从细胞中释放。首先,TM536 插入内质网(ER)膜,然后,由于其跨膜结构域的低疏水性,它从 ER 膜中逸出,并遵循常规的分泌途径,在没有蛋白水解参与的情况下被释放到细胞外腔室中。这种特殊的分泌机制产生了一种可溶性 TM536,与传统分泌的可溶性 TM 形式相比,它的硫酸软骨素糖胺聚糖修饰较差,因此介导凝血酶依赖性蛋白 C(PC)激活的能力较差。我们还表明,TM536 的细胞内运输发生改变,滞留在内质网相关降解早期分泌途径中,并增加对 ER 相关降解的敏感性。正如预期的那样,ER 相关降解的激活增加了 TM536 的降解并减少了其释放。TM536 在细胞表面的表达水平较低,其在脂质筏样膜微区的分布也发生改变,导致细胞表面凝血酶依赖性 PC 激活降低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/dccea17522b5/BLOODA_ADV-2024-013546-gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/83da272b0b72/BLOODA_ADV-2024-013546-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/3a4a31406ca8/BLOODA_ADV-2024-013546-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/ec1a7a97ae9b/BLOODA_ADV-2024-013546-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/716831dc855c/BLOODA_ADV-2024-013546-gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/254c42da6449/BLOODA_ADV-2024-013546-gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/f5c6571734ad/BLOODA_ADV-2024-013546-gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/51ddcceac46f/BLOODA_ADV-2024-013546-gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/dccea17522b5/BLOODA_ADV-2024-013546-gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/83da272b0b72/BLOODA_ADV-2024-013546-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/3a4a31406ca8/BLOODA_ADV-2024-013546-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/ec1a7a97ae9b/BLOODA_ADV-2024-013546-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/716831dc855c/BLOODA_ADV-2024-013546-gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/254c42da6449/BLOODA_ADV-2024-013546-gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/f5c6571734ad/BLOODA_ADV-2024-013546-gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/51ddcceac46f/BLOODA_ADV-2024-013546-gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2da5/11532747/dccea17522b5/BLOODA_ADV-2024-013546-gr7.jpg

相似文献

1
Thrombomodulin (p.Cys537Stop) is released from cells by an unusual membrane insertion/leakage mechanism.血栓调节蛋白(p.Cys537Stop)通过一种不寻常的膜插入/渗漏机制从细胞中释放出来。
Blood Adv. 2024 Nov 12;8(21):5467-5478. doi: 10.1182/bloodadvances.2024013546.
2
Thrombomodulin-mediated catabolism of protein C by pleural mesothelial and vascular endothelial cells.血栓调节蛋白介导的胸膜间皮细胞和血管内皮细胞对蛋白C的分解代谢。
Thromb Haemost. 2007 Sep;98(3):627-34.
3
Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling.血栓调节蛋白通过上调细胞外信号调节激酶/髓样白血病细胞-1 信号通路保护血管内皮细胞免受钙调神经磷酸酶抑制剂诱导的细胞毒性。
Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2259-70. doi: 10.1161/ATVBAHA.112.251157. Epub 2012 Jul 12.
4
Thrombomodulin functions as a plasminogen receptor to modulate angiogenesis.血栓调节蛋白作为纤溶酶原受体调节血管生成。
FASEB J. 2013 Nov;27(11):4520-31. doi: 10.1096/fj.13-227561. Epub 2013 Aug 13.
5
Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin?为什么携带THBD基因c.1611C>A(p.Cys537X)无义突变的患者可溶性血栓调节蛋白水平较高?
PLoS One. 2017 Nov 16;12(11):e0188213. doi: 10.1371/journal.pone.0188213. eCollection 2017.
6
Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells.人血管内皮细胞蛋白 C 和凝血酶激活的纤溶抑制物的激活。
J Thromb Haemost. 2016 Feb;14(2):366-74. doi: 10.1111/jth.13222. Epub 2016 Feb 1.
7
Humic acid reduces protein-C-activating cofactor activity of thrombomodulin of human umbilical vein endothelial cells.腐殖酸降低人脐静脉内皮细胞血栓调节蛋白的蛋白C激活辅因子活性。
Br J Haematol. 1998 Apr;101(1):16-23. doi: 10.1046/j.1365-2141.1998.00651.x.
8
Recombinant human soluble thrombomodulin delivers bounded thrombin to antithrombin III: thrombomodulin associates with free thrombin and is recycled to activate protein c.重组人可溶性血栓调节蛋白将结合的凝血酶递送至抗凝血酶III:血栓调节蛋白与游离凝血酶结合并循环利用以激活蛋白C。
Thromb Haemost. 1993 Sep 1;70(3):418-22.
9
Probing the activation of protein C by the thrombin-thrombomodulin complex using structural analysis, site-directed mutagenesis, and computer modeling.利用结构分析、定点诱变和计算机建模探究凝血酶-血栓调节蛋白复合物对蛋白C的激活作用。
Proteins. 1999 May 1;35(2):218-34. doi: 10.1002/(sici)1097-0134(19990501)35:2<218::aid-prot8>3.0.co;2-2.
10
Association of the thrombomodulin gene c.1418C>T polymorphism with thrombomodulin levels and with venous thrombosis risk.血栓调节蛋白基因 c.1418C>T 多态性与血栓调节蛋白水平及静脉血栓形成风险的关联。
Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1435-40. doi: 10.1161/ATVBAHA.113.301360. Epub 2013 Mar 21.

本文引用的文献

1
Proteasome activation: A novel strategy for targeting undruggable intrinsically disordered proteins.蛋白酶体激活:靶向不可成药的固有无序蛋白的新策略。
Bioorg Chem. 2024 Apr;145:107217. doi: 10.1016/j.bioorg.2024.107217. Epub 2024 Feb 16.
2
Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures.循环血栓调节蛋白:释放机制、检测方法以及在疾病和医疗程序中的水平
TH Open. 2022 Jul 11;6(3):e194-e212. doi: 10.1055/a-1801-2055. eCollection 2022 Jul.
3
The aminosterol Claramine inhibits β-secretase 1-mediated insulin receptor cleavage.
氨甾醇类 Claramine 抑制β-分泌酶 1 介导的胰岛素受体裂解。
J Biol Chem. 2021 Jul;297(1):100818. doi: 10.1016/j.jbc.2021.100818. Epub 2021 May 23.
4
Glucose-regulated protein (GRP78) is an important cell surface receptor for viral invasion, cancers, and neurological disorders.葡萄糖调节蛋白(GRP78)是病毒入侵、癌症和神经疾病的重要细胞表面受体。
IUBMB Life. 2021 Jun;73(6):843-854. doi: 10.1002/iub.2502. Epub 2021 May 15.
5
Characterisation of a novel thrombomodulin c.1487delC,p.(Pro496Argfs*10) variant and evaluation of therapeutic strategies to manage the rare bleeding phenotype.新型血栓调节蛋白 c.1487delC,p.(Pro496Argfs*10) 变异的特征描述,以及管理罕见出血表型的治疗策略评估。
Thromb Res. 2021 Jan;197:100-108. doi: 10.1016/j.thromres.2020.11.002. Epub 2020 Nov 9.
6
Thrombomodulin as a Physiological Modulator of Intravascular Injury.血栓调节蛋白作为血管内损伤的生理调节剂。
Front Immunol. 2020 Sep 16;11:575890. doi: 10.3389/fimmu.2020.575890. eCollection 2020.
7
A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency.一个新的家系与血栓调节蛋白相关的凝血障碍,其中纤维蛋白溶解的延迟部分被共同遗传的 TAFI 缺乏所减弱。
J Thromb Haemost. 2020 Sep;18(9):2209-2214. doi: 10.1111/jth.14990. Epub 2020 Jul 23.
8
Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders.蛋白酶体激活作为靶向蛋白毒性疾病的新治疗方法。
J Med Chem. 2019 Jul 25;62(14):6469-6481. doi: 10.1021/acs.jmedchem.9b00101. Epub 2019 Mar 14.
9
Exploring traditional and nontraditional roles for thrombomodulin.探索血栓调节蛋白的传统和非传统作用。
Blood. 2018 Jul 12;132(2):148-158. doi: 10.1182/blood-2017-12-768994. Epub 2018 Jun 4.
10
Giant Plasma Membrane Vesicles: An Experimental Tool for Probing the Effects of Drugs and Other Conditions on Membrane Domain Stability.巨型质膜囊泡:一种用于探究药物及其他条件对膜结构域稳定性影响的实验工具。
Methods Enzymol. 2018;603:129-150. doi: 10.1016/bs.mie.2018.02.007. Epub 2018 Mar 15.